Last reviewed · How we verify
Mitomycin C
Mitomycin C is an antibiotic that alkylates DNA and creates cross-links, preventing DNA replication and causing cell death.
Mitomycin C is an antibiotic that alkylates DNA and creates cross-links, preventing DNA replication and causing cell death. Used for Gastric cancer, Colorectal cancer, Breast cancer.
At a glance
| Generic name | Mitomycin C |
|---|---|
| Also known as | any brand is permitted, Mutamycin, Mitomycin, MMC, Mutamycin® (trade name) |
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Drug class | DNA alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Mitomycin C is a naturally derived antibiotic that acts as a DNA-alkylating agent. After metabolic activation, it covalently binds to DNA and forms interstrand cross-links, which block DNA replication and transcription. This leads to apoptosis and cell death, making it effective against rapidly dividing cancer cells.
Approved indications
- Gastric cancer
- Colorectal cancer
- Breast cancer
- Bladder cancer
- Head and neck cancer
Common side effects
- Myelosuppression (bone marrow suppression)
- Nausea and vomiting
- Alopecia (hair loss)
- Mucositis
- Hemolytic uremic syndrome
- Pulmonary toxicity
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Preserflo MicroShunt Versus Trabeculectomy (NA)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (PHASE1)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin C CI brief — competitive landscape report
- Mitomycin C updates RSS · CI watch RSS
- University of Erlangen-Nürnberg Medical School portfolio CI